title: [Psychiatry].
abstract: During the year 2005 much of the attention was given to the debate on the risk of suicide during treatments with selective serotonin reuptake inhibitors. Our review concludes with a moderate increased risk of suicidal behaviour but not a risk of death by suicide. Caution, not panic, is indicated, particularly for children and adolescents given that, in this age group, benefits of these drugs have not been well established. We also report two synthesis concerning the latest developments in the fields of cognitive psychotherapy for depressive disorders (rather stimulating news) and of pharmacotherapy for borderline personality disorders (no breaking news).
authors.affiliation: Service de psychiatrie adulte, HUG, Chêne-Bourg. gilles.bertschy@hcuge.ch
authors.forename: G
authors.initials: G
authors.lastname: Bertschy
authors.forename: R
authors.initials: R
authors.lastname: Barbe
authors.forename: N
authors.initials: N
authors.lastname: Gervasoni
authors.forename: C
authors.initials: C
authors.lastname: Bryois
mesh_terms: D000293:Adolescent; D000367:Age Factors; D001883:Borderline Personality Disorder / Q000188:drug therapy; D002648:Child; D015928:Cognitive Behavioral Therapy; D003866:Depressive Disorder / Q000628:therapy; D006801:Humans; D011570:Psychiatry / Q000639:trends*; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013405:Suicide
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors